CLPUB00123
Cinatl J., Gussetis E.S., Cinatl J. Jr., Ebener U., Mainke M., Schwabe D., Doerr H.-W., Kornhuber B., Gerein V.
Differentiation arrest in neuroblastoma cell culture.
J. Cancer Res. Clin. Oncol. 116 Suppl. 1:9-9(1990)

PubMed=8949988; DOI=10.1097/00001813-199609000-00008
Cinatl J. Jr., Cinatl J., Scholz M., Hernaiz Driever P., Henrich D., Kabickova H., Vogel J.-U., Doerr H.-W., Kornhuber B.
Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.
Anticancer Drugs 7:766-773(1996)

PubMed=9201287
Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G., Gumbel H.O.C., Rabenau H.F., Kornhuber B., Doerr H.-W.
Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes.
Neoplasma 44:91-95(1997)

PubMed=16142320; DOI=10.3892/ijo.27.4.1029
Kotchetkov R., Hernaiz Driever P., Cinatl J., Michaelis M., Karaskova J., Blaheta R.A., Squire J.A., von Deimling A., Moog J., Cinatl J. Jr.
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Int. J. Oncol. 27:1029-1037(2005)

PubMed=16151587
Bedrnicek J.B., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr., Michaelis M., Cinatl J., Eckschlager T.
Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
Neoplasma 52:415-419(2005)

PubMed=17505515; DOI=10.1038/sj.bjc.6603777; PMCID=PMC2359931
Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E., Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Br. J. Cancer 96:1699-1706(2007)

PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856
Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K., Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Cancer Res. 69:416-421(2009)

PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738
Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D., Cinatl J. Jr.
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:e243.1-e243.8(2011)

PubMed=22476102; DOI=10.1038/cddis.2012.35; PMCID=PMC3358013
Michaelis M., Rothweiler F., Agha B., Barth S., Voges Y., Loschmann N., von Deimling A., Breitling R., Doerr H.-W., Rodel F., Speidel D., Cinatl J. Jr.
Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
Cell Death Dis. 3:e294.1-e294.8(2012)

PubMed=24466371; DOI=10.1593/tlo.13544; PMCID=PMC3890703
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332
Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T., Cinatl J. Jr.
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015)

PubMed=27517323; DOI=10.18632/oncotarget.11160; PMCID=PMC5295411
Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B., Blight B.A., Cinatl J. Jr.
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
Oncotarget 7:58051-58064(2016)

PubMed=27735941; DOI=10.1038/cddis.2016.257; PMCID=PMC5133961
Voges Y., Michaelis M., Rothweiler F., Schaller T., Schneider C., Politt K., Mernberger M., Nist A., Stiewe T., Wass M.N., Rodel F., Cinatl J. Jr.
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Cell Death Dis. 7:e2410.1-e2410.11(2016)

PubMed=31581737; DOI=10.3390/cells8101194; PMCID=PMC6830094
Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R., Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M., Michaelis M.
Intact-cell MALDI-ToF mass spectrometry for the authentication of drug-adapted cancer cell lines.
Cells 8:1194.1-1194.12(2019)